0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Morphine and Naloxone on Serum Levels of Luteinizing Hormone and Prolactin in Prepubertal Male and Female Rats

      , ,

      Neuroendocrinology

      S. Karger AG

      Morphine, Naloxone, LH, Prepubertal rats, PRL

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effects of morphine (M) and naloxone (N) on serum levels of luteinizing hormone (LH) and prolactin (PRL) in prepubertal male and female rats were investigated. N raised serum LH concentrations in female rats at 10, 15, 20, 25 and 30 days of age, but increased serum LH levels in male prepubertal rats only at 30 days of age. M significantly depressed serum LH values in both sexes only at 15 days of age. M increased serum PRL levels in immature rats of both sexes in all age groups, except in 25-day-old males, whereas N decreased serum PRL only in 25-day-old male rats. These data show that there are differences in the pituitary LH and PRL responses to M or N of immature as compared to the responses previously reported in mature rats, and suggest that the endogenous opioid peptides may have a role in regulating LH and PRL secretion in immature rats.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1979
          1979
          26 March 2008
          : 29
          : 4
          : 288-292
          Affiliations
          Department of Physiology, Neuroendocrine Research Laboratory, Michigan State University, East Lansing, Mich.
          Article
          122935 Neuroendocrinology 1979;29:288–292
          10.1159/000122935
          514456
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Comments

          Comment on this article